BioMarin Pharmaceutical
BMRN
NZ$97.70
Share price
0.15%
Change (1 day)
-31.41%
Change (1 year)
Categories
Revenue for BioMarin Pharmaceutical (BMRN)
Revenue in 2025 (TTM): NZ$4.98 Billion
According to BioMarin Pharmaceutical's latest financial reports the company's current revenue (TTM 
) is NZ$4.95 Billion. In 2024 the company made a revenue of NZ$5.06 Billion an increase over the revenue in the year 2023 that were of NZ$3.82 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BioMarin Pharmaceutical from 1999 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | NZ$4.98 B | -1.55% |
| 2024 | NZ$5.06 B | 32.28% |
| 2023 | NZ$3.82 B | 15.88% |
| 2022 | NZ$3.30 B | 22.14% |
| 2021 | NZ$2.70 B | 4.83% |
| 2020 | NZ$2.57 B | 1.91% |
| 2019 | NZ$2.53 B | 13.81% |
| 2018 | NZ$2.22 B | 20.19% |
| 2017 | NZ$1.84 B | 14.72% |
| 2016 | NZ$1.61 B | 24.01% |
| 2015 | NZ$1.30 B | 35.7% |
| 2014 | NZ$0.95 B | 43.56% |
| 2013 | NZ$0.66 B | 9.66% |
| 2012 | NZ$0.60 B | 7.63% |
| 2011 | NZ$0.56 B | 15.95% |
| 2010 | NZ$0.48 B | 9.11% |
| 2009 | NZ$0.44 B | -12.51% |
| 2008 | NZ$0.51 B | 221.89% |
| 2007 | NZ$0.15 B | 32.79% |
| 2006 | NZ$0.11 B | 218.27% |
| 2005 | NZ$37.55 M | |
| 2002 | NZ$26.59 M | 6.84% |
| 2001 | NZ$24.89 M | -10.5% |
| 2000 | NZ$27.81 M | 108.25% |
| 1999 | NZ$13.35 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Ultragenyx Pharmaceutical RARE | NZ$0.99 B | -79.98% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | NZ$0.10 B | -97.84% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | NZ$0.43 B | -91.20% | 🇺🇸 USA |
 Sanofi SNY | NZ$79.52 B | 1,506.60% | 🇫🇷 France |
 Amicus Therapeutics
FOLD | NZ$0.91 B | -81.59% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | NZ$0.89 B | -81.88% | 🇺🇸 USA |